In vitro activity of colistin in combination with tigecycline against carbapenem-resistant Acinetobacter baumannii strains isolated from patients with ventilator-associated pneumonia

International Journal of Medical Sciences

Volumn 12, Issue 9, 2015, Pages 695-700

  Cikman, Aytekin ^a   Gulhan, Baris ^a   Aydin, Merve ^a   Ceylan, Mehmet Resat ^b   Parlak, Mehmet ^c   Karakecili, Faruk ^a   Karagoz, Alper ^d  

^a ERZINCAN UNIVERSITY   (Turkey)

^b Viransehir State Hospital   (Turkey)

^c YUZUNCU YIL UNIVERSITY   (Turkey)

^d Public Health Institution of Turkey   (Turkey)

Author keywords

Acinetobacter baumannii; Carbapenem resistant; Colistin; Tigecycline; Ventilator associated pneumonia

Indexed keywords

AMIKACIN; AZTREONAM; CARBAPENEM; CEFEPIME; CEFOPERAZONE PLUS SULBACTAM; CEFOTAXIME; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; TETRACYCLINE; TIGECYCLINE; ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE; MINOCYCLINE;

ACINETOBACTER BAUMANNII; ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; CLINICAL ARTICLE; DRUG EFFICACY; EPSILOMETER TEST; FEMALE; HUMAN; IN VITRO STUDY; MALE; MIC50; MIC90; NONHUMAN; PULSED FIELD GEL ELECTROPHORESIS; VENTILATOR ASSOCIATED PNEUMONIA; ADOLESCENT; AGED; ANALOGS AND DERIVATIVES; CHILD; COMBINATION DRUG THERAPY; DRUG EFFECTS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; PRESCHOOL CHILD; VERY ELDERLY; YOUNG ADULT;

ACINETOBACTER BAUMANNII; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CARBAPENEMS; CHILD; CHILD, PRESCHOOL; COLISTIN; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MINOCYCLINE; PNEUMONIA, VENTILATOR-ASSOCIATED; YOUNG ADULT;

EID: 84940906758     PISSN: 14491907     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijms.11988     Document Type: Article

References (41)

1. Gupta S, Boville BM, Blanton R, et al. A multicentered prospective analysis of diagnosis, risk factors, and outcomes associated with pediatric ventilator- associated pneumonia. Pediatr Crit Care Med. 2015; 16: 65-73
2. Charles MP, Kali A, Easow JM, et al. Ventilator-associated pneumonia. Australas Med J. 2014; 7: 334-344
3. Ranjan N, Chaudhary U, Chaudhry D, et al. Ventilator-associated pneumonia in a tertiary care intensive care unit: Analysis of incidence, risk factors and mortality. Indian J Crit Care Med. 2014; 18: 200-204
4. Perez KK, Olsen RJ, Musick WL, et al. Integrating rapid diagnostic and antimicrobial stewardship improves outcomes in patients with antibiotic-resistant Gram-negative bacteremia. J Infect. 2014; 69: 216-225
5. Bassi GL, Ferrer M, Marti JD, et al. Ventilator-associated pneumonia. Semin Respir Crit Care Med. 2014; 35: 469-481
6. Landelle C, Legrand P, Lesprit P, et al. Protracted outbreak of multidrug- resistant Acinetobacter baumannii after intercontinental transfer of colonized patients. Infect Control Hosp Epidemiol. 2013; 34: 119-124
7. Sandiumenge A, Rello J. Ventilator-associated pneumonia caused by ESKAPE organisms: cause, clinical features, and management. Curr Opin Pulm Med. 2012; 18: 187-193
8. Bobik P, Siemiatkowski A. Ventilator-associated pneumonia and other infections. Pneumonol Alergol Pol. 2014; 82: 472-480
9. Cohen R, Shimoni Z, Ghara R, et al. Effect of a ventilator-focused intervention on the rate of Acinetobacter baumannii infection among ventilated patients. Am J Infect Control. 2014; 42: 996-1001
10. Chittawatanarat K, Jaipakdee W, Chotirosniramit N, et al. Microbiology, resistance patterns, and risk factors of mortality in ventilator-associated bacterial pneumonia in a Northern Thai tertiary-care university based general surgical intensive care unit. Infect Drug Resist. 2014; 7: 203-210
11. Pogue JM, Mann T, Barber KE, et al. Carbapenem-resistant Acinetobacter baumannii: epidemiology, surveillance and management. Expert Rev Anti Infect Ther. 2013; 11: 383-393
12. Tsakiridou E, Makris D, Daniil Z, et al. Acinetobacter baumannii infection in prior ICU ned occupants is an independent risk factor for subsequent cases of ventilator-associated pneumonia. Biomed Res Int. 2014; 2014: 193516
13. Mortensen BL, Skaar EP. Host-microbe interactions that shape the pathogenesis of Acinetobacter baumannii infection. Cell Microbiol. 2012; 14: 1336-1344
14. Deveci A, Coban AY, Acicbe O et al. In vitro effects of sulbactam combinations with different antibiotic groups against clinical Acinetobacter baumannii isolates. J Chemother. 2012; 24: 247-252
15. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005; 171: 388-416
16. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; Twenty-fourth informational supplement (Document M100-S24). Wayne, PA: CLSI. 2014
17. Navon-Venezia S, Leavitt A, Carmeli Y. High tigecycline resistance in multidrug- resistant Acinetobacter baumannii. J Antimicrob Chemother. 2007; 59: 772-774
18. Durmaz R, Otlu B, Koksal F, et al. The optimization of a rapid pulsed-field gel electrophoresis protocol for the typing of Acinetobacter baumannii, Escherichia coli and Klebsiella spp. Jpn J Infect Dis. 2009; 62: 372-377
19. Tenover FC, Arbeit RD, Goering RV, et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol. 1995; 33: 2233-2239
20. Eraç B, Yılmaz FF, Hoşgör Limoncu M, et al. Investigation of the virulence factors of multidrug-resistant Acinetobacter baumannii isolates. Mikrobiyol Bul. 2014; 48: 70-81
21. Simsek F, Gedik H, Yildirmak MT, et al. Colistin against colistin- only-susceptible Acinetobacter baumannii-related infections: Monotherapy or combination theraphy? Indian J Med Microbiol. 2012; 30: 448-452
22. Arroyo LA, Mateos I, González V et al. In vitro activities of tigecycline, minocycline, and colistin-tigecycline combination against multi- and pandrug- resistant clinical isolates of Acinetobacter baumannii group. Antimicrob Agents Chemother. 2009; 53: 1295-1296
23. Doi Y, Murray GL, Peleg AY, et al. Acinetobacter baumannii: evolution of antimicrobial resistance-treatment options. Semin Respir Crit Care Med. 2015; 36: 85-98
24. Taşbakan MS, Pullukçu H, Ekren PK, et al. Colistin use in ventilator-associated pneumonia due to panresistant Pseudomonas aeruginosa and Acinetobacter baumannii. Mikrobiyol Bul. 2009; 43: 61-70
25. Shrestha A, Soriano SM, Song M, et al. Intravenous colistin-induced acute respiratory failure: A case report and a review of literature. Int J Crit Illn Inj Sci. 2014; 4: 266-270
26. Dong X, Chen F, Zhnag Y et al. In vitro activities of rifampin, colistin, sulbactam and tigecycline tested alone and in combination against extensively drug-resistant Acinetobacter baumannii. J Antibiot (Tokyo). 2014; 67: 677-680
27. Kehl SC, Dowzicky MJ. Global assessment of antimicrobial susceptibility among Gram-negative organisms collected from pediatric patients between 2004 and 2012: results from the Tigecycline Evaluation and Surveillance Trial. J Clin Microbiol. 2015; 53: 1286-1293
28. Deng M, Zhu MH, Li JJ, et al. Molecular epidemiology and mechanisms of tigecycline resistance in clinical isolates of Acinetobacter baumannii from a Chinese university hospital. Antimicrob Agents Chemother. 2014; 58: 297-303
29. Tasbakan MS, Pullukcu H, Sipahi OR, et al. Is tigecyclin a good choice in the treatment of multidrug-resistant Acinetobacter baumannii pneumonia? J Chemother. 2011; 23: 345-349
30. Ni W, Cui J, Liang B et al. In vitro effects of tigecycline in combination with colistin (polymyxin E) and sulbactam against multidrug-resistant Acinetobacter baumannii. J Antibiot (Tokyo). 2013; 66: 705-708
31. Karaoglan I, Zer Y, Bosnak VK et al. In vitro synergistic activity of colistin with tigecycline or β-lactam antibiotic/β-lactamase inhibitor combinations against carbapenem-resistant Acinetobacter baumannii. J Int Med Res 2013; 41: 1830-1837
32. Pillai SK, Moellering RC, Eliopoulos GM. Antimicrobial combinations. In: Lorian V, ed. Antibiotics in Laboratory Medicine, 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2005: 365-440
33. Michalopoulos AS, Falagas ME. Colistin: recent data on pharmacodynamics properties and clinical efficacy in critically ill patients. Ann Intensive Care. 2011; 1: 30
34. Lee HJ, Bergen PJ, Bulitta JB, et al. Synergistic activity of colistin and rifampin combination against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother. 2013; 57: 3738-3745
35. Kwon SH, Ahn HL, Han OY, et al. Efficacy and safety profile comparison of colistin and tigecycline on the extensively drug resistant Acinetobacter baumannii. Biol Pharm Bull. 2014; 37: 340-346
36. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis. 2005; 40: 1333-1341
37. Livermore DM. Tigecycline: what is it, and where should it be used? J Antimicrob Chemother. 2005; 56: 611-614
38. Peleg AY, Potoski BA, Rea R, et al. Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. J Antimicrob Chemother. 2007; 59: 128-131
39. Stein GE, Craig WA. Tigecycline: a critical analysis. Clin Infect Dis. 2006; 43: 518-524
40. Basri DF, Xian LW, Abdul Shukor NI. Bacteriostatic antimicrobial combination: antagonistic interaction between epsilon-viniferin and vancomycin against methicilin-resistant Staphylococcus aureus. Biomed Res Int. 2014; 2014: 461756
41. Ocampo PS, Lázár V, Papp B, et al. Antagonism between bacteriostatic and bactericidal antibiotics is prevalent. Antimicrob Agents Chemother. 2014; 58: 4573-4582.